Transaction DateRecipientSharesTypePriceValue
28th December 2020James V Caruso37,037Open or private purchase$1.35$49,999.95
28th December 2020Jarrod Longcor29,630Open or private purchase$1.35$40,000.50
28th December 2020Dov Elefant7,407Open or private purchase$1.35$9,999.45
16th December 2020Stephen A Hill7,500Exercise of derivative$0.00
5th June 2020Dov Elefant4,348Open or private purchase$1.15$4,978.46
5th June 2020James V Caruso21,740Open or private purchase$1.15$24,892.30
5th June 2020Jarrod Longcor65,218Open or private purchase$1.15$74,674.61
4th June 2020Stephen A Hill18,000Open or private purchase$1.08$19,438.20
3rd February 2020Jarrod Longcor40,000Grant/award etc.$2.71$108,400.00
3rd February 2020James V Caruso100,000Grant/award etc.$2.71$271,000.00
Cellectar Bio Sciences
Cellectar Bio Sciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; and CLR 125, which intends to treat micro metastatic disease.

Ticker: CLRB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1279704
Employees: 8
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags